CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer´s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany / Boston, USA, January 7, 2021 – Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain
DGAP-News: CureVac / Key word(s): Alliance/Agreement
CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
07.01.2021 / 08:30
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
- Companies enter into a collaboration and services agreement
- Bayer to support CureVac in numerous areas, including development and supply of CVnCoV
- CureVac benefits from Bayer s expertise and established infrastructure
- Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany/ Boston, USA, January 7, 2021 -
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its exper